The transformative efficacy of EV-Pembro has ushered in a new, aggressive treatment philosophy for both muscle-invasive and metastatic bladder cancer. The approach is to administer the combination upfront to gain rapid disease control, and only then make subsequent decisions about surgery, radiation, or further therapy.

Trials like CREST and Potomac show a consistent but modest event-free survival benefit when adding a PD-1 inhibitor to BCG for high-risk non-muscle-invasive bladder cancer. However, this comes with significant toxicity and no current overall survival benefit, creating a complex risk-benefit discussion for patients.

Major trials in prostate (PEACE-2), bladder (Keynote B15), and kidney cancer (LITESPARK-022) showcase a common strategy: moving potent systemic therapies into earlier, curative-intent settings. This approach of using the best drugs sooner aims to improve long-term outcomes, though it also raises questions about toxicity and overtreatment.

The practice-changing Keynote B15 trial showed strong efficacy for neoadjuvant EV-Pembro. However, about half of patients discontinued treatment due to side effects. This creates a clinical paradox: patients who complete the full regimen may be over-treated, while those who stop early due to toxicity may be under-treated, complicating patient management and counseling.

High relapse rates (~70%) in surgery-alone arms of recent trials suggest most patients with muscle-invasive bladder cancer (MIBC) already have micrometastatic disease. This reframes the disease, prioritizing early systemic therapy over immediate surgery to achieve control and potential cure.

In high-risk non-muscle invasive bladder cancer (NMIBC), trials like CREST and POTOMAC show adding a systemic immune checkpoint inhibitor to BCG therapy introduces significant toxicity. The benefit is primarily in local control, which may not justify the risk, especially with other effective intravesical options available.

Giving EV Pembro perioperatively for muscle-invasive bladder cancer provides the best chance for a cure. Waiting to use it in the first-line metastatic setting is a major gamble, as many patients relapse and may not get a second chance at effective therapy. The consensus is to use the best treatment upfront.

A key lesson in bladder cancer is that patient attrition is rapid between lines of therapy; many who relapse from localized disease never receive effective later-line treatments. This reality provides a strong rationale for moving the most effective therapies, like EV-pembrolizumab, to earlier settings to maximize the number of patients who can benefit.

While an approved option, systemic checkpoint inhibitors like pembrolizumab come with a significant downside. Clinicians counsel patients on a 15% chance of life-altering toxicities like permanent endocrine disease, a critical risk when the treatment often only delays, not prevents, cystectomy.